NVP-BEP795 and NVP-BEP800: Novel, fragment derived orally bioavailable small molecule Hsp90 inhibitors with potent antitumor activity

被引：0
|
作者：
Massey, Andrew
Brough, Paul
Jensen, Michael
Ruetz, Stephan
Schoepfer, Joseph
Workman, Paul
Garcia-Echeverria, Carlos
Drysdale, Martin
机构：
[1] Vernalis Ltd, Cambridge, England
[2] Novartis Inst Biomed Res, Basel, Switzerland
[3] 3Canc Res UK Ctr Canc Therapeut, Sutton, Surrey, England
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4677
引用
收藏
页数：2
相关论文
共 35 条
  • [11] Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800 radiosensitize tumor cells through induction of DNA damage, protraction of DNA repair and cell cycle impairment
    Sting, L.
    Stuehmer, T.
    Chatterjee, M.
    Jensen, M.
    Flentje, M.
    Djuzenova, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 66 - 66
  • [12] Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
    L Stingl
    T Stühmer
    M Chatterjee
    M R Jensen
    M Flentje
    C S Djuzenova
    British Journal of Cancer, 2010, 102 : 1578 - 1591
  • [13] Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
    Stingl, L.
    Stuehmer, T.
    Chatterjee, M.
    Jensen, M. R.
    Flentje, M.
    Djuzenova, C. S.
    BRITISH JOURNAL OF CANCER, 2010, 102 (11) : 1578 - 1591
  • [14] NVP-BEP800 / VER-82576: A potent orally active Hsp90 chaperone inhibitor evolved by SBDD from Vernalis fragment (\#8220;SeeDs\#8221;) hits and in silco screening hits
    Brough, Paul
    Massey, Andrew
    Jensen, Michael
    Schoepfer, Joseph
    Barril, Xavier
    Hubbard, Rod
    Dymock, Brian
    Surgenor, Alan
    Wright, Lisa
    Cozens, Bob
    Eccles, Sue
    Sharp, Swee
    Raynaud, Flo
    Workman, Paul
    Garcia-Echeverria, Carlos
    Wood, Mike
    Drysdale, Martin
    CANCER RESEARCH, 2009, 69
  • [15] NVP-AUY922:: A novel small molecule HSP90 inhibitor with potent in vivo antitumor efficacy
    Jensen, Michael Rugaard
    Schoepfer, Joseph
    Radimersky, Thomas
    Massey, Andrew
    Brueggen, Josef
    Schweitzer, Alain
    Pfaar, Ulrike
    Ruetz, Stephan
    Guy, Chantal
    Buckler, Alan
    Schnell, Christian
    Cozens, Robert
    Brough, Paul
    Drysdale, Martin
    Quadt, Cornelia
    Garcia-Echeverria, Carlos
    Chene, Patrick
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3521S - 3521S
  • [16] Simultaneous radiation and Hsp90 inhibition by NVP-AUY922 or NVP-BEP800 is more efficient in tumor cell killing than drug-first modality followed by irradiation
    Niewidok, N.
    Wack, L-J
    Stingl, L.
    Katzer, A.
    Sukhorukov, V. L.
    Flentje, M.
    Djuzenova, C. S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 125 - 126
  • [17] HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias
    Mshaik, Rony
    Simonet, John
    Georgievski, Aleksandra
    Jamal, Layla
    Bechoua, Shaliha
    Ballerini, Paola
    Bellaye, Pierre-Simon
    Mlamla, Zandile
    Pais de Barros, Jean-Paul
    Geissler, Audrey
    Francin, Pierre-Jean
    Girodon, Francois
    Garrido, Carmen
    Quere, Ronan
    BLOOD CANCER JOURNAL, 2021, 11 (03)
  • [18] HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias
    Rony Mshaik
    John Simonet
    Aleksandra Georgievski
    Layla Jamal
    Shaliha Bechoua
    Paola Ballerini
    Pierre-Simon Bellaye
    Zandile Mlamla
    Jean-Paul Pais de Barros
    Audrey Geissler
    Pierre-Jean Francin
    François Girodon
    Carmen Garrido
    Ronan Quéré
    Blood Cancer Journal, 11
  • [19] NVP-AUY922:: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
    Jensen, Michael Rugaard
    Schoepfer, Joseph
    Radimerski, Thomas
    Massey, Andrew
    Guy, Chantale T.
    Brueggen, Josef
    Quadt, Cornelia
    Buckler, Alan
    Cozens, Robert
    Drysdale, Martin J.
    Garcia-Echeverria, Carlos
    Chene, Patrick
    BREAST CANCER RESEARCH, 2008, 10 (02)
  • [20] Preclinical Activity of the Novel Orally Bioavailable HSP90 Inhibitor NVP-HSP990 against Multiple Myeloma Cells
    Stuehmer, Thorsten
    Iskandarov, Kamol
    Gao, Zhenhai
    Bumm, Thomas
    Grella, Evelyn
    Jensen, Michael R.
    Einsele, Hermann
    Chatterjee, Manik
    Bargou, Ralf C.
    ANTICANCER RESEARCH, 2012, 32 (02) : 453 - 462
1234